(Q38847251)

7 September 2017

1 reference

title

A clinical and biological perspective of human myeloid-derived suppressor cells in cancer (English)

1 reference

7 September 2017

1

Christopher Shipp

1 reference

7 September 2017

5

Graham Pawelec

1 reference

7 September 2017

Lisa Speigl

2

1 reference

PubMed ID

27236468

7 September 2017

Nicole Janssen

series ordinal

3

1 reference

PubMed ID

27236468

7 September 2017

Alexander Martens

series ordinal

4

1 reference

7 September 2017

28 May 2016

1 reference

Cellular and Molecular Life Sciences

7 September 2017

1 reference

7 September 2017

73

1 reference

7 September 2017

21

1 reference

7 September 2017

4043-4061

1 reference

https://scigraph.springernature.com/pub.10.1007/s00018-016-2278-y

7 September 2017

0 references

cites work

Coordinated regulation of myeloid cells by tumours

1 reference

https://api.crossref.org/works/10.1007%2FS00018-016-2278-Y

The growing diversity and spectrum of action of myeloid-derived suppressor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-016-2278-Y

The terminology issue for myeloid-derived suppressor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-016-2278-Y

History of myeloid-derived suppressor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-016-2278-Y

Myeloid-derived suppressor cells in B cell malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-016-2278-Y

The immunobiology of myeloid-derived suppressor cells in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-016-2278-Y

On the armament and appearances of human myeloid-derived suppressor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-016-2278-Y

IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-016-2278-Y

Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-016-2278-Y

A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-016-2278-Y

Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-016-2278-Y

Transcriptional regulation of myeloid-derived suppressor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-016-2278-Y

Noncanonical NF-κB activation mediates STAT3-stimulated IDO upregulation in myeloid-derived suppressor cells in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-016-2278-Y

Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-016-2278-Y

Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-016-2278-Y

Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-016-2278-Y

Distinct myeloid suppressor cell subsets correlate with plasma IL-6 and IL-10 and reduced interferon-alpha signaling in CD4⁺ T cells from patients with GI malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-016-2278-Y

Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-016-2278-Y

Functional characterization of human Cd33+ and Cd11b+ myeloid-derived suppressor cell subsets induced from peripheral blood mononuclear cells co-cultured with a diverse set of human tumor cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-016-2278-Y

Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-016-2278-Y

Myeloid derived suppressor cells - a new therapeutic target in the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-016-2278-Y

Myeloid-derived suppressor cells are associated with disease progression and decreased overall survival in advanced-stage melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-016-2278-Y

Elevated chronic inflammatory factors and myeloid-derived suppressor cells indicate poor prognosis in advanced melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-016-2278-Y

Computational algorithm-driven evaluation of monocytic myeloid-derived suppressor cell frequency for prediction of clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-016-2278-Y

Vemurafenib reverses immunosuppression by myeloid derived suppressor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-016-2278-Y

Immunosuppressive CD14+HLA-DRlow/- monocytes in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-016-2278-Y

Correlation between frequencies of blood monocytic myeloid-derived suppressor cells, regulatory T cells and negative prognostic markers in patients with castration-resistant metastatic prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-016-2278-Y

Increase in CD14+HLA-DR -/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-016-2278-Y

A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-016-2278-Y

Increased CD14(+)HLA-DR (-/low) myeloid-derived suppressor cells correlate with extrathoracic metastasis and poor response to chemotherapy in non-small cell lung cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-016-2278-Y

A circulating subpopulation of monocytic myeloid-derived suppressor cells as an independent prognostic/predictive factor in untreated non-small lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-016-2278-Y

IL-6-stimulated CD11b+ CD14+ HLA-DR- myeloid-derived suppressor cells, are associated with progression and poor prognosis in squamous cell carcinoma of the esophagus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-016-2278-Y

Circulating myeloid-derived suppressor cells correlate with clinical outcome in Hodgkin Lymphoma patients treated up-front with a risk-adapted strategy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-016-2278-Y

STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-016-2278-Y

Circulating CD14(+)HLA-DR(-/low) myeloid-derived suppressor cell is an indicator of poor prognosis in patients with ESCC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-016-2278-Y

Myeloid-Derived Suppressor Cells as an Immune Parameter in Patients with Concurrent Sunitinib and Stereotactic Body Radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-016-2278-Y

Granulocytic myeloid-derived suppressor cells are cryosensitive and their frequency does not correlate with serum concentrations of colony-stimulating factors in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-016-2278-Y

TLR9-Targeted STAT3 Silencing Abrogates Immunosuppressive Activity of Myeloid-Derived Suppressor Cells from Prostate Cancer Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-016-2278-Y

Increased levels of granulocytic myeloid-derived suppressor cells in peripheral blood and tumour tissue of pancreatic cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-016-2278-Y

Increased myeloid-derived suppressor cells in gastric cancer correlate with cancer stage and plasma S100A8/A9 proinflammatory proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-016-2278-Y

CD15+/CD16low human granulocytes from terminal cancer patients: granulocytic myeloid-derived suppressor cells that have suppressive function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-016-2278-Y

Circulating hematopoietic stem and progenitor cells are myeloid-biased in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-016-2278-Y

Clinical significance of plasmacytoid dendritic cells and myeloid-derived suppressor cells in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-016-2278-Y

Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-016-2278-Y

Circulating and tumor-infiltrating myeloid-derived suppressor cells in patients with colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-016-2278-Y

Patients with pancreatic adenocarcinoma exhibit elevated levels of myeloid-derived suppressor cells upon progression of disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-016-2278-Y

Uterine cervical cancer displaying tumor-related leukocytosis: a distinct clinical entity with radioresistant feature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-016-2278-Y

Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-016-2278-Y

Myeloid-derived suppressor cells enhance stemness of cancer cells by inducing microRNA101 and suppressing the corepressor CtBP2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-016-2278-Y

Myeloid-derived suppressor cells predict survival of patients with advanced melanoma: comparison with regulatory T cells and NY-ESO-1- or melan-A-specific T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-016-2278-Y

Functional T Cells Targeting NY-ESO-1 or Melan-A Are Predictive for Survival of Patients With Distant Melanoma Metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-016-2278-Y

Presence of circulating Her2-reactive CD8 + T-cells is associated with lower frequencies of myeloid-derived suppressor cells and regulatory T cells, and better survival in older breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-016-2278-Y

Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-016-2278-Y

Limited induction of tumor cross-reactive T cells without a measurable clinical benefit in early melanoma patients vaccinated with human leukocyte antigen class I-modified peptides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-016-2278-Y

Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-016-2278-Y

Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-016-2278-Y

Immunological factors influencing clinical outcome in lung cancer patients after telomerase peptide vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-016-2278-Y

Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-016-2278-Y

Toward harmonized phenotyping of human myeloid-derived suppressor cells by flow cytometry: results from an interim study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-016-2278-Y

Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-016-2278-Y

Melanoma-educated CD14+ cells acquire a myeloid-derived suppressor cell phenotype through COX-2-dependent mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-016-2278-Y

Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: a prognostic model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-016-2278-Y

How regulatory T cells work

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-016-2278-Y

L-arginine availability regulates T-lymphocyte cell-cycle progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-016-2278-Y

ROS function in redox signaling and oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-016-2278-Y

Regulation of immune responses by prostaglandin E2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-016-2278-Y

Role of Stat3 in suppressing anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-016-2278-Y

CLL-cells induce IDOhi CD14+HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-016-2278-Y

Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-016-2278-Y

Immunosuppressive activity of CD14+ HLA-DR- cells in squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-016-2278-Y

All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-016-2278-Y

Treatment with lenalidomide induces immunoactivating and counter-regulatory immunosuppressive changes in myeloma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-016-2278-Y

Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c+ dendritic cell frequency predicts progression-free survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-016-2278-Y

The effects of gemcitabine and capecitabine combination chemotherapy and of low-dose adjuvant GM-CSF on the levels of myeloid-derived suppressor cells in patients with advanced pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-016-2278-Y

Tumor-induced CD14+HLA-DR (-/low) myeloid-derived suppressor cells correlate with tumor progression and outcome of therapy in multiple myeloma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-016-2278-Y

Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-016-2278-Y

Sunitinib pretreatment improves tumor-infiltrating lymphocyte expansion by reduction in intratumoral content of myeloid-derived suppressor cells in human renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-016-2278-Y

Ipilimumab treatment results in an early decrease in the frequency of circulating granulocytic myeloid-derived suppressor cells as well as their Arginase1 production.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-016-2278-Y

Intralesional treatment of stage III metastatic melanoma patients with L19-IL2 results in sustained clinical and systemic immunologic responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-016-2278-Y

Tadalafil reduces myeloid-derived suppressor cells and regulatory T cells and promotes tumor immunity in patients with head and neck squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-016-2278-Y

Tadalafil augments tumor specific immunity in patients with head and neck squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-016-2278-Y

Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-016-2278-Y

Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-016-2278-Y

A Study of Zoledronic Acid as Neo-Adjuvant, Perioperative Therapy in Patients with Resectable Pancreatic Ductal Adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-016-2278-Y

The induction of human myeloid derived suppressor cells through hepatic stellate cells is dose-dependently inhibited by the tyrosine kinase inhibitors nilotinib, dasatinib and sorafenib, but not sunitinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-016-2278-Y

Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-016-2278-Y

Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-016-2278-Y

Dissemination and publication of research findings: an updated review of related biases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-016-2278-Y

Reporting bias in medical research - a narrative review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-016-2278-Y

Publication bias in clinical research

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-016-2278-Y

Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-016-2278-Y

Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-016-2278-Y

Plasticity of human Th17 cells and iTregs is orchestrated by different subsets of myeloid cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-016-2278-Y

Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-016-2278-Y

Myeloid-derived suppressor cells impair the quality of dendritic cell vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-016-2278-Y

Identification of a New Subset of Myeloid Suppressor Cells in Peripheral Blood of Melanoma Patients With Modulation by a Granulocyte-Macrophage Colony-Stimulation Factor–Based Antitumor Vaccine

21 January 2018

1 reference

12 December 2020

Population alterations of L-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14⁻/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer

1 reference

12 December 2020

TGF-β function in immune suppression

1 reference

12 December 2020

Increased frequency and clinical significance of myeloid-derived suppressor cells in human colorectal carcinoma

1 reference

12 December 2020

Myeloid cells obtained from the blood but not from the tumor can suppress T-cell proliferation in patients with melanoma.

1 reference

12 December 2020

The clinical and prognostic significance of CD14(+)HLA-DR(-/low) myeloid-derived suppressor cells in hepatocellular carcinoma patients receiving radiotherapy

1 reference

12 December 2020

Increased circulating immunosuppressive CD14(+)HLA-DR(-/low) cells correlate with clinical cancer stage and pathological grade in patients with bladder carcinoma

1 reference

12 December 2020

Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion

1 reference

12 December 2020

Vascular endothelial growth factor-trap overcomes defects in dendritic cell differentiation but does not improve antigen-specific immune responses

1 reference

12 December 2020

Circulating and tumor-infiltrating myeloid cell subsets in patients with bladder cancer

1 reference

12 December 2020

Increased frequencies of CD11b(+) CD33(+) CD14(+) HLA-DR(low) myeloid-derived suppressor cells are an early event in melanoma patients

1 reference

12 December 2020

Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients.

1 reference

12 December 2020

Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign

1 reference

12 December 2020

Inhibition of tumor-derived prostaglandin-e2 blocks the induction of myeloid-derived suppressor cells and recovers natural killer cell activity

1 reference

12 December 2020

CD14(+)HLA-DR(low/-) expression: A novel prognostic factor in chronic lymphocytic leukemia

1 reference

12 December 2020

Increased circulating myeloid-derived suppressor cells correlate with cancer stages, interleukin-8 and -6 in prostate cancer.

1 reference

12 December 2020

Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells

1 reference

12 December 2020

10.1007/S00018-016-2278-Y

Identifiers

DOI

1 reference

7 September 2017

1 reference

PubMed ID

27236468